MENU
+Compare
EBS
Stock ticker: NYSE
AS OF
Oct 14, 04:59 PM (EDT)
Price
$9.11
Change
-$0.19 (-2.04%)
Capitalization
496.17M

EBS Emergent Biosolutions Forecast, Technical & Fundamental Analysis

Emergent BioSolutions Inc offers public health products to the government and healthcare providers... Show more

Industry: #Biotechnology
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EBS with price predictions
Oct 13, 2025

Aroon Indicator for EBS shows an upward move is likely

EBS's Aroon Indicator triggered a bullish signal on October 13, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator showed a similar pattern. In of the 180 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 24, 2025. You may want to consider a long position or call options on EBS as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EBS just turned positive on September 25, 2025. Looking at past instances where EBS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

EBS moved above its 50-day moving average on September 09, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EBS moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where EBS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EBS broke above its upper Bollinger Band on October 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.925) is normal, around the industry mean (17.612). P/E Ratio (3.550) is within average values for comparable stocks, (72.701). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.982). EBS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.631) is also within normal values, averaging (47.252).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EBS is expected to report earnings to fall 70.81% to 4 cents per share on October 29

Emergent Biosolutions EBS Stock Earnings Reports
Q3'25
Est.
$0.05
Q2'25
Beat
by $0.26
Q1'25
Beat
by $0.22
Q4'24
Beat
by $0.46
Q3'24
Beat
by $1.27
The last earnings report on August 06 showed earnings per share of 15 cents, beating the estimate of -10 cents. With 192.64K shares outstanding, the current market capitalization sits at 496.17M.
A.I. Advisor
published General Information

General Information

a manufacturer of biopharmaceutical products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Biotechnology
Address
300 Professional Drive
Phone
+1 240 631-3200
Employees
1600
Web
https://www.emergentbiosolutions.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCHSX32.92N/A
N/A
Putnam Global Health Care C
NBMOX52.76N/A
N/A
Neuberger Berman Small Cap Growth Tr
PGIUX16.16N/A
N/A
Virtus Duff & Phelps Global Infras I
HWNIX14.67N/A
N/A
Hotchkis & Wiley International Value I
PWJDX34.92N/A
N/A
PGIM Jennison International Opps R4

EBS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+2.54%
SIGA - EBS
43%
Loosely correlated
+0.49%
VTRS - EBS
40%
Loosely correlated
+1.23%
ELAN - EBS
36%
Loosely correlated
+1.42%
PAHC - EBS
30%
Poorly correlated
+0.52%
ZOMDF - EBS
29%
Poorly correlated
-5.31%
More

Groups containing EBS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+2.54%
Pharmaceuticals: Generic
industry (221 stocks)
34%
Loosely correlated
+0.24%